...
首页> 外文期刊>Cells >Major Tumor Suppressor and Oncogenic Non-Coding RNAs: Clinical Relevance in Lung Cancer
【24h】

Major Tumor Suppressor and Oncogenic Non-Coding RNAs: Clinical Relevance in Lung Cancer

机译:主要的肿瘤抑制物和致癌非编码RNA:肺癌的临床相关性。

获取原文

摘要

Lung cancer is the leading cause of cancer deaths worldwide, yet there remains a lack of specific and sensitive tools for early diagnosis and targeted therapies. High-throughput sequencing techniques revealed that non-coding RNAs (ncRNAs), e.g., microRNAs and long ncRNAs (lncRNAs), represent more than 80% of the transcribed human genome. Emerging evidence suggests that microRNAs and lncRNAs regulate target genes and play an important role in biological processes and signaling pathways in malignancies, including lung cancer. In lung cancer, several tumor suppressor/oncogenic microRNAs and lncRNAs function as biomarkers for metastasis and prognosis, and thus may serve as therapeutic tools. In this review, recent work on microRNAs and lncRNAs is introduced and briefly summarized with a focus on potential biological and therapeutic applications.
机译:肺癌是全球癌症死亡的主要原因,但是仍然缺乏用于早期诊断和靶向治疗的特异性和敏感性工具。高通量测序技术表明,非编码RNA(ncRNA),例如microRNA和长ncRNA(lncRNA),占转录的人类基因组的80%以上。新兴证据表明,microRNA和lncRNA调节靶基因,并在包括肺癌在内的恶性肿瘤的生物过程和信号传导途径中发挥重要作用。在肺癌中,几种抑癌/致癌微RNA和lncRNA充当转移和预后的生物标志物,因此可以用作治疗工具。在这篇综述中,介绍了有关microRNA和lncRNA的最新工作,并简要概述了其潜在的生物学和治疗应用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号